Clinical Trial Update: Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT [Phase 2]

View source ↗

Summary

Phase 2 trial investigating relapse prophylaxis with N-803 after allogeneic HSCT in AML and MDS patients has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• N-803

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS) | Phase 2 | Status: COMPLETED | Results posted: 2023-11-03